CD274 and non-small cell lung carcinoma: In a study of patients with stage II unresectable non-small cell lung cancer, the addition of the PD-L1 inhibitor durvalumab after 42 days of concurrent radiotherapy was associated with progression-free survival and overall survival benefits of patients after immunotherapy.